FDA OKs First ' Biosimilar ' Drug to Fight Cancer, Mvasi
THURSDAY, Sept. 14, 2017 -- The first approval of a biosimilar drug to treat cancer was announced Thursday by the U.S. Food and Drug Administration.
Mvasi (bevacizumab-awwb) was approved as a biosimilar to Avastin (bevacizumab) for the treatment of...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | General Medicine